… to imatinib in blocking proliferation of BCR–ABL-dependent CML cell lines. Nilotinib inhibits
BCR–ABL … cell lines containing BCR–ABL point mutants commonly seen in patients with …

… This led to the development of nilotinib, a high affinity … of imatinib and nilotinib with BCR-ABL.
The reduced requirement for hydrogen bonding with nilotinib compared to imatinib, allows …

… BCR-ABL1 IS > 10% at 3 months; moreover, more patients in … nilotinib arms versus the imatinib
arm achieved BCR-ABL1 IS … BCR-ABL1 IS ≤ 10% at 3 months was higher in the nilotinib …

… nilotinib, a more potent BCR-ABL … nilotinib and imatinib on BCR-ABL TK activity. Although
the maximal inhibition of CRKL phosphorylation by nilotinib and imatinib was similar, nilotinib …

… , imatinib is not completely specific for BCR-ABL … of BCR-ABL tyrosine kinase, nilotinib.We
demonstrate that inhibition of BCR-ABL auto-phosphorylation by either imatinib or nilotinib …

… various BCR-ABL inhibitors, we demonstrate that first, second and third generation BCR-ABL …
The first-generation inhibitor imatinib was proven safe, with evident benefit for plasma lipid …

… BCR-ABL protein in a similar manner to imatinib, although nilotinib has a higher binding
affinity and ● In the phase I study, which involved administraselectivity for the ABL kinase.[5,12,…

… Nilotinib is more effective in this respect than imatinib. We have shown that nilotinib induces
apoptosis in imatinib-resistant K562 CML cells which have the wild-type BCR– ABL fusion …

… many imatinib mesylate–resistant BCR-ABL kinase … BCR-ABL cells to compare incidence
and types of KD mutants emerging in the presence of imatinib mesylate, dasatinib, and nilotinib…

… inhibition of Bcr–Abl signalling, by either Imatinib or Nilotinib, … a possible link between
Bcr–Abl signalling and ROS production … associated with Imatinib and Nilotinib treatment in CML. …